MgSO4 Combined With Rocuronium Priming

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01389791

Enrollment

100

Registered

2011-07-08

Start date

2011-05-31

Completion date

2012-01-31

Last updated

2012-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Relaxation

Keywords

muscle relaxation, magnesium sulfate, rocuronium

Brief summary

Priming with either rocuronium or MgSO4 is known to accelerate the effect of rocuronium on muscle relaxation. The purpose of this study is to define the effect of MgSO4 on the rocuronium-priming.

Detailed description

Acceleration of muscle relaxation is beneficial in rapid-sequence intubation. If MgSO4 combined with priming is efficient in accelerating muscle relaxation, it would be an interesting alternative to rapid-sequence intubation.

Interventions

DRUGmagnesium sulfate

Patients in this group receive intravenous MgSO4 50mg/kg before administration of rocuronium (induction dose).

DRUGpriming

Patients in this group receive 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.

DRUGmagnesium sulfate and priming

Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* patients of ASA Ⅰ-Ⅱ * aged 18\ 65 * scheduled to undergo elective surgery under general anesthesia

Exclusion criteria

* risk of pulmonary aspiration * anticipated airway difficulty * reactive airway disease * allergic to study drugs * neuromuscular / cardiovascular/ renal/ hepatic disease * atrioventricular conduction disturbance * BMI \< 18.5 or \> 24.9 * chronic treatment with calcium channel blocker * medications which affect muscle relaxation

Design outcomes

Primary

Measure	Time frame
time from injection of induction dose of rocuronium until 95% depression of TOF	time from injection of induction dose of rocuronium until 95% depression of TOF, upto 5 min

Secondary

Measure	Time frame	Description
rocuronium duration	time from injection of induction dose of rocuronium until train-of-four count reaches two.	time from injection of induction dose of rocuronium until train-of-four count reaches two.
intubating condition	time from injection of induction dose of rocuronium until tracheal intubation.	rapid sesequence intubation condition is evaluated.

Countries

South Korea

Contacts

Primary ContactMihyun Kim, MD

snmd56@yahoo.com82-31-787-2034

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026